publicações selecionadas
-
artigo académico
- Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+ß7 integrin+ T cells and anti-SARS-CoV-2 IgA response. Nature Communications. 2023
- Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+ß7 integrin+ T cells and anti-SARS-CoV-2 IgA response. Nature Communications. 2023
- PlexinA4 mediates cytotoxic T cell trafficking and exclusion in cancer. Cancer Immunology Research. 2021
- Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Frontiers in Immunology. 2021
-
artigo de revista
- Influence of HOTAIR rs920778 and rs12826786 genetic variants on prostate cancer risk and progression-free survival. Biomarkers in Medicine. 2018
- Development, characterization, antioxidant and hepatoprotective properties of poly(¿-caprolactone) nanoparticles loaded with a neuroprotective fraction of Hypericum perforatum. International Journal of Biological Macromolecules. 2018
- Loss of Caveolin-1 in Metastasis-Associated Macrophages Drives Lung Metastatic Growth through Increased Angiogenesis. Cell Reports. 2017
- Crosstalk between glial and glioblastoma cells triggers the "go-or-grow" phenotype of tumor cells. Cell Communication and Signaling. 2017
- Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis. Journal of Neuro-Oncology. 2017
- Neuroprotective activity of Hypericum perforatum and its major components. Frontiers in Plant Science. 2016
- Transcriptional profiling of HOXA9-regulated genes in human glioblastoma cell models. Genomics Data. 2015
- A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget. 2015
- A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget. 2015
-
documento
- Blood CD8+ß7+ T cells and serum IgA humoral response against SARS-CoV-2 antigens characterize Post COVID-19 condition at six months post infection. 2023
- A Transcriptomic Signature Mediated by HOXA9 Promotes Human Glioblastoma Initiation, Aggressiveness and Resistance to Temozolomide 2015
- HOXA9 promotes glioblastoma initiation, aggressiveness and resistance to therapy 2014